EcoDrugPlus

Tyrosinase

Ensembl ID : ENSATEG00000001766
Gene Symbol: TYR
3 Cross references
196 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSATEG00000019262
Gene Symbol: TH
3 Cross references
188 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSATEG00000021035
Gene Symbol: TYK2
2 Cross references
196 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin-Like And Egf-Like Domains 1

Ensembl ID : ENSATEG00000020549
Gene Symbol: TIE1
3 Cross references
207 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Ufo

Ensembl ID : ENSATEG00000008244
Gene Symbol: LOC113168239
3 Cross references
188 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSATEG00000003974
Gene Symbol: UTS2R
4 Cross references
92 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSATEG00000021300
Gene Symbol: KRAS
3 Cross references
208 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSATEG00000023275
Gene Symbol: AKT2
1 Cross references
199 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSATEG00000010208
Gene Symbol: AKT3A
1 Cross references
203 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSATEG00000020042
Gene Symbol: RELA
3 Cross references
201 Possible Orthologues:

Vascular Endothelial Growth Factor Aa

Ensembl ID : ENSATEG00000001238
Gene Symbol: VEGFAA
2 Cross references
180 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSATEG00000003293
Gene Symbol: VEGFAB
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).